

To: Ms Casemore PS/MS(L)

From: Christine Corrigan HSD1C

Date: 5 December 1997

Copies: Ms Anderson PS/SofS  
Mr Griffiths PS/CE  
Dr Shepherd PS/CMO  
Dr Winyard HSD  
Mr Hewlett HSD1  
Dr McGovern HSD1  
Mr Paley FPA-FAS

**Letter from Sir Colin Walker about the impact of the recommendations from the UK Haemophilia Centre Directors (UKHCDO) on the Bio Products Laboratory.**

1. Sir Colin Walker wrote to Baroness Jay on 26 November about the potential service and financial implications for the Bio Products Laboratory of the UKHCDO recommendation that, in view of the risk posed by nvCJD, clinicians should only use either recombinant or non-UK derived blood products. Sir Colin copied his letter to Dr Winyard.
2. Dr Winyard has already written to Sir Colin in response to a letter from the Chief Executive, John Adey, of the same date (attached for information) which raised a range of further issues for discussion. I attach a copy of Dr Winyard's reply.
3. In the light of the content of that letter, MS(L) may wish simply to send a very brief acknowledgement to Sir Colin on the lines of the attached draft.

Christine Corrigan  
HSD1C  
416, WEL  
Ext: **GRO-C**

04/12/97